>No fun for COR longs today, but perhaps a buying opportunity.<
Provided you think the company still has credibility.
What if there is no bona fide interest in CX-717 and the ampakine platform by Big Pharma and all the talk about a pending deal is just… talk? If that’s the case, the stock still has a lot of room to fall, IMO.
Good luck.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”